Reducing inflammation in colorectal cancer surgery
Reducing Inflammatory Syndrome in Surgery - Colorectal (RISIS-CR) Trial
PHASE3 · National University Hospital, Singapore · NCT06646809
This study is testing if giving a safe supplement before colorectal cancer surgery can help older patients reduce inflammation and recover better after their operation.
Quick facts
| Phase | PHASE3 |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 45 Years and up |
| Sex | All |
| Sponsor | National University Hospital, Singapore (other) |
| Locations | 4 sites (Singapore, Singapore and 3 other locations) |
| Trial ID | NCT06646809 on ClinicalTrials.gov |
What this trial studies
This trial aims to assess the inflammatory response of patients prior to elective colorectal cancer surgery and administer a preventive anti-inflammatory treatment to those exhibiting excessive pro-inflammatory responses. The intervention involves the use of alpha-ketoglutarate, a geroprotector supplement recognized as safe by the FDA, which may help reduce postoperative complications associated with systemic inflammatory response. By personalizing treatment based on individual inflammatory profiles, the study seeks to improve surgical outcomes and recovery for older patients undergoing colorectal surgery.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 45 years and older who are scheduled for elective colorectal cancer surgery.
Not a fit: Patients undergoing emergency colorectal cancer surgery or those who are pregnant or cognitively impaired may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce postoperative complications and improve recovery times for patients undergoing colorectal cancer surgery.
How similar studies have performed: Other studies have shown mixed results with anti-inflammatory treatments in surgical settings, making this approach both innovative and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged at least 45 years old * Undergoing elective colorectal cancer surgery * Able to give informed consent Exclusion Criteria: * Undergoing emergency colorectal cancer surgery * Unable to give informed consent * Females who are pregnant * Cognitively impaired patients
Where this trial is running
Singapore, Singapore and 3 other locations
- National University Hospital — Singapore, Singapore, Singapore (RECRUITING)
- Ng Teng Fong General Hospital — Singapore, Singapore (RECRUITING)
- Sengkang General Hospital — Singapore, Singapore (RECRUITING)
- Singapore General Hospital — Singapore, Singapore (RECRUITING)
Study contacts
- Principal investigator: Lian Kah Ti — National University Hospital, Singapore
- Study coordinator: Lian Kah Ti
- Email: anatilk@nus.edu.sg
- Phone: 6567724200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colorectal Cancer, Geroprotector, Alpha-ketoglutarate